hotspot -WSS

hotspot

author：comprehensive 2025-09-29 19:05:40 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： A Greenpeace activist is fined for crash

WSS

CDC advisory panel says seniors 'may' get RSV vaccine

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

EU fines Illumina $475 million over Grail acquisition

CDC advisory panel says seniors 'may' get RSV vaccine

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Drug firms test therapies to halt Alzheimer’s before symptoms arise

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Bright Health sells Medicare Advantage business to Molina

AstraZeneca challenges Medicare drug negotiation program

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AstraZeneca challenges Medicare drug negotiation program

Psychedelics group wrestles with new pharma identity

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Continuity nursing helped my family in our darkest PICU moments

AstraZeneca challenges Medicare drug negotiation program

Supreme Court strikes down use of affirmative action

Britney Spears to release memoir, 'The Woman In Me,' later this year

hotspot

AstraZeneca bets AAV gene therapy will still deliver the goods

France's anti

EU fines Illumina $475 million over Grail acquisition

How to make Best Hospitals ratings actually useful for patients

Grail's uphill battle for Medicare to cover its cancer screening test

Winners, losers from Medicare’s list of drugs subject to price talks

Wikipedia

hotspot

knowledge

knowledge